N4 Pharma secures patent in Europe for Nuvec, expects China to follow

(Alliance News) - N4 Pharma PLC on Friday said it has secured a European patent in relation to ...

Alliance News 1 October, 2021 | 8:50AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - N4 Pharma PLC on Friday said it has secured a European patent in relation to Nuvec, specifically in respect of its composition, particulate materials and methods for making the particulate materials.

This patent adds to existing grants in Australia and Japan.

Nuvec is a silica nanoparticle delivery system for cancer and vaccine treatments.

In addition, the Derby, England-based pharmaceutical company said it it has been informed by the Chinese Patent Office of its intention to grant the patent in China in relation to Nuvec.

Discussions with other key patent authorities in the US, Canada and India are also continuing, the company noted.

"We are delighted that the European Patent Office has now formally granted the European patent which is now validated across Europe. This achieves another key step in our IP strategy where we are also making excellent progress following the notice of allowance made recently by the Chinese Patent Office for the potentially huge market of China and the ongoing discussions in other key jurisdictions," said Chief Executive Nigel Theobald.

AIM-listed N4 Pharma shares were trading 17% higher in London on Friday morning at 9.31 pence each.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
N4 Pharma PLC 8.60 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.